A full list of side effects can be found on the Wegovy site
With semaglutide, the process takes longer because the medication remains in the body for longer
It just means that in clinical trials, midlife women are grouped into broader categories, making it hard to draw firm conclusions about how well GLP-1s work for this unique stage of life as compared to other populations
For example, the STEP 1 trial of once-weekly semaglutide (2.4 mg) in people without diabetes achieved a ~15% average body weight reduction over 68 weeks (source), with a mean baseline BMI of ~38 (source)
If fatigue persists beyond 68 weeks, discuss with your provider whether dosage reduction, switching to a different GLP-1 formulation, or adding complementary medications may help
However, these side effects have also been associated with other glucagon-like peptide 1 medications currently available for weight management